readthroughSign in
Nov 16, 2026People

Nasus Pharma names Nir Sassi chief financial officer, effective November 11, 2026

The intranasal drug developer tapped a finance executive with past CFO roles at two Nasdaq companies as it prepares a pivotal Phase 3 study of its lead candidate NS002.

Nasus Pharma Ltd. (NYSE American: NSRX) announced the appointment of Nir Sassi as Chief Financial Officer, effective November 11, 2026.1 The company formalized the move on November 11, 2026, when it appointed Sassi as CFO and entered into an employment agreement with him dated the same day.1 The company said it expects to enter into its standard form of indemnification agreement with Sassi on the same terms used for its other directors and executive officers.1 It also disclosed that there are no related party transactions involving Sassi requiring disclosure under Item 7.B of Form 20-F.1

Sassi's background includes service as Chief Financial Officer of Indaptus Therapeutics, Inc. (Nasdaq: INDP) from August 2021 to April 2026.1 Before that role, he was CFO of Intec Pharma Ltd., which traded on Nasdaq under the ticker NTEC before that listing ended, and he began his career as a senior manager at PricewaterhouseCoopers in Israel, according to the filing. He holds an economics and accounting degree from Ben-Gurion University of the Negev in Israel and is a certified public accountant there.

CEO Brendan O'Grady said Sassi joins at an important time as the company prepares to initiate its planned NS002 pivotal study and finalize pre-commercial plans, with NS002 advancing toward a pivotal Phase 3 study in the fourth quarter of 2026 and a topline data readout in the first quarter of 2027.1 NS002 is described as an intranasal epinephrine treatment being developed for Type I allergic reactions, including anaphylaxis.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.